 FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a key step in the process towards an Investigational New Drug IND to study first-in-human products leading to potential marketing approval. LOS ANGELES, Feb. 24, 2020 GLOBE NEWSWIRE -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that the FDA has scheduled an Initial Targeted Engagement for Regulatory Advice on CBER Products INTERACT meeting for early June. 